Forcefield raises £5.5M for protein-based heart attack drug – BioWorld

Nuala Moran at BioWorld spoke to Prof. Mauro Giacca, scientific founder of Forcefield, Richard Francis, CEO, and Chris Hollowood, Chief Investment Officer of Syncona, on Forcefield’s launch, it’s backing from Syncona and how Forcefield aims to protect heart function following myocardial infarction, helping sustain cardiac function and preventing clinical changes in the heart outline our plans.

Read Article

About Forcefield Therapeutics Ltd.

Forcefield Therapeutics Ltd (Forcefield Tx) is a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes. Forcefield Tx was founded by scientists, industry experts and investors with a shared purpose to revolutionise treatment following acute myocardial infarction (MI).

Forcefield’s unique approach can both retain and protect heart cells, minimising the impact of MI and preventing the cascade of events that may lead to subsequent heart failure. Forcefield Tx is led by a proven team with a record of success from discovery to commercialisation and is backed by leading FTSE 250 healthcare company, Syncona.

Forcefield Therapeutics
Rolling Stock Yard
188 York Way
N7 9AS